У статті наведені результати клінічного дослідження з вивчення ефективності та переносимості ДД «Альцинара» виробництва ПАТ НВЦ «Борщагівський ХФЗ» порівняно з Плацебо у добровольців з гіперхолестеринемією. Добровольці основної (30 осіб) та контрольної груп (30 осіб) амбулаторно приймали ДД «Альцинара» протягом 90 днів по 2 таблетки 3 рази на день та Плацебо (по 2 таблетки 3 рази на день протягом 90 днів) відповідно. Оцінку ефективності ДД «Альцинара»/Плацебо проводили через 45±2 та 91±2 днів від початку прийому ДД «Альцинара»/Плацебо на підставі динаміки показників ліпідограми; переносимість оцінювали на підставі реєстрації та аналізу побічних реакцій/побічних явищ. Згідно з отриманими результатами ДД «Альцинара» сприяє поліпшенню ліпідного профілю у добровольців з гіперхолестеринемією через 3 місяці прийому, про що свідчить статистично значуща різниця між групами за основним критерієм ефективності – частка добровольців, віднесених до категорії «Застосування ефективне». Гіполіпідемічний вплив ДД «Альцинара» проявляється не тільки у зниженні рівня ліпопротеїдів низької щільності, а також і тригліцеридів. Досліджуваний продукт здатен підвищувати вміст ліпопротеїдів високої щільності, зниження яких є окремим предиктором розвитку та прогресування атеросклерозу. Небажані побічні ефекти у разі прийому досліджуваних продуктів виникли загалом у 23,7% добровольців та відзначалися у кожній групі без статистично значущих відмінностей за частотою. Найбільш часто спостерігалось виникнення диспепсії (16,13% випадків) та головного болю – 16,13% випадків. Таким чином, гіполіпідемічну дію ДД «Альцинара» можна вважати доведеною, тому її застосування як спеціального харчового продукту для тривалого використання особам з гіперхолестеринемією та/або особам зі схильністю до гіперхолестеринемії (обтяжений родинний анамнез, надлишкова маса тіла, нераціональне харчування, цукровий діабет тощо) буде зменшувати ризик розвитку атеросклерозу та його фатальних наслідків.

1. Katz J, Rosenbloom BN. The golden anniversary of Melzack and Wall’s gate control theory of pain: Celebrating 50 years of pain research and management. Pain Res Manag. 2015;20(6):285–6. doi: 10.1155/2015/865487. CrossRef Google Scholar

Combined dry extract BNO 1016 is a herbal drug commonly used for rhinosinusitis therapy. It is known that a significant role in rhinosinusitis pathogenesis is played by an inflammatory reaction in maxillary sinuses of the nasal cavity. At the initial stage of any inflammation the largest impact is caused by leukotrienes. Major chronic rhinosinusitis (CRS) according to the guideline EPOS-2020 include facial pain as clinical diagnostic criteria for rhinosinusitis. Therefore, it is reasonable to study the analgesic effects of the combined dry extract BNO 1016 on the model of zymozan- induced hyperalgesia. The tested drug is the combined dry extract BNO 1016 ("Bionorica SE", Germany) at different dose levels. The reference drug is ibuprofen. Leukotriene hyperalgesia was induced by subplantar injection of zymozan into the paw of Wistar rats. Pain threshold was evaluated with Ugo-Basil analgesimeter and analgesic activity was calculated together with mean effective dose (ED50) with help of the Probit Analysis. The highest analgesic activity was observed at a dose level of 500 mg/kg of BNO 1016 during all time-points of the experiment and reached 169.5% 3h after hyperalgesia onset. The analgesic activity of BNO 1016 at doses of 50 mg/kg in 1h, 2h, 3h after induction hyperalgesia, 150 mg/kg and 500 mg/ kg was credibly higher than that of Ibuprofen at all time-points of the experiment. Based on the experimental data, the index of ED50 for analgesic activity of BNO 1016 was calculated with Probit Analysis. The combined dry extract BNO 1016 shows a high level of analgesic activity in the leukotriene-depended hyperalgesia model, which is very promising for the improvement of treatment of patients with CRS, but additional preclinical and clinical researches are reasonable.

Kidney and urinary tract diseases play an important role in the disease distribution in most countries of the world. The pharmaceutical industry offers many means for the treatment and prevention of these diseases, but there is a trending tendency to pay more attention to herbal medicines, their empirical application and scientific study. The aim of this research is to study anti-inflammatory properties of standardized herbal composition BNO 2103 in a model of paw inflammation in rats caused by different phlogogens to justify the use of it in the treatment of chronic kidney disease (CKD). Materials and methods. The experimental study was performed using 90 male white outbreed rats weighing 150–200 g, which were divided into 3 series of 30 animals each, each series included 3 groups. Inflammation of the paw was induced by subplantar administration of phlogogens – zymosan, histamine and serotonin. The study agent and the reference drug, diclofenac sodium, were administered intragastrically (i. g.) once. Edema was observed and recorded, and anti-inflammatory activity (AIA) was assessed in 0.5, 1.0, 2.0, 3.0 and 6.0 hours after phlogogen injection. Results. BNO 2103 showed a remarkable anti-exudative effect in the model of zymosan and histamine edema, being significantly superior to diclofenac sodium. In the serotonin edema model, BNO 2103 was significantly superior to the comparator by the endpoints, showing the moderate but prolonged anti-exudative effect. Conclusions. BNO 2103 has the significant anti-inflammatory effect, exerting an inhibitory effect on exudative inflammation caused by various phlogogens (zymosan, histamine, serotonin), mainly acting on the lipoxygenase pathway of arachidonic acid conversion, which is most likely due to the presence of flavonoids. This allows us to consider BNO 2103 as a promising drug for the treatment of CKD.

КП Волинської обласної ради «Волинська

The aim. To develop conceptual framework of the strategy for a reasonable transition from original to generic medicines by complex implementation of proper bioequivalence studies and sufficient therapeutic drug monitoring management. Materials and methods. To conduct the study, we used the lists of medicines included in the state reimbursement program “Dostupny Liky” (Affordable Medicines), and materials of reports on medicines public procurement provided on the website of the Ministry of Health of Ukraine and the National Health Service of Ukraine, as well as information data on the results of studies of the quality and effectiveness of these drugs provided by the Rx-Index website. In the course of the study, the methods of logical analysis, SWOT analysis, and statistical evaluation of results, Kingdon’s Policy Streams Approach and the method of flowcharts construction were used. The concept of evidence-based medicine substitution formation in Ukraine was designed applying the Policy Streams Approach. Results. The analysis of public procurement programs for drugs for the period 2018–2020, as well as the analysis of drugs included in the new list under the “Dostupny Liky” (Affordable Medicines) program, carried out in the course of the study, showed that the level of evidence of data on assessing their effectiveness remains low. At the same time, more than 1.5 billion UAH (~ 50 mln USD) is spent annually on the purchase of such drugs and reimbursement of their cost, and the question of the optimal selection and monitoring of pharmacotherapy with these drugs remains open. A structural model has been developed, in which three basic levels are identified: provision of regulatory and financial components, executive and the level of implementation of the results. The SWOT-analysis of the strengths and weaknesses, as well as external opportunities and threats for the implementation of the conceptual framework made it possible to substantiate the advantages and reveal the possibilities of attracting clinical centers of universities and research institutions to the implementation of the concept. A framework for the interaction of a research center with health care institutions in the implementation of therapeutic drug monitoring was developed for low-income and low-middle income countries on the example of Ukraine. Distribution of responsibilities was proposed and the basic principles of interaction between performers of therapeutic drug monitoring were highlighted. Conclusions. Based on the results of the analysis of the evidence of the quality and effectiveness of drugs included in public procurement and in reimbursement programs, the key problems of organizing pharmaceutical provision of an appropriate level of quality for a number of chronic diseases requiring lifelong therapy were identified. The conceptual framework of evidence-based original medicines substitution to generic counterparts have been formed; and the ways of its implementation in the conditions of scarce financial resources on the example of Ukraine have been substantiated

The aim of this work was to evaluate the effectiveness of quercetin addition to the treatment regimen for patients with COVID-19 associated pneumonia. Materials and methods. The effectiveness of two dosage forms of quercetin was studied in 200 patients, who were divided equally into the main and control groups. The main group patients received quercetin in addition to the basic therapy: intravenous drip of Quercetin/Polyvinylirolidone during the first 10 days followed by oral administration of Quercetin/Pectin over the next 10 days. Patients from the control group received only the basic therapy drugs. The study evaluated the dynamics of the disease symptoms (saturation level, respiratory rate, body temperature, cough, general weakness), as well as laboratory markers (C-reactive protein (CRP), ferritin, D-dimer). Results. Two dosage forms of quercetin consistently used in addition to the basic therapy improve pulmonary gas exchange and accelerate the lung function recovery. This is evidenced by a statistically significant majority of patients with positive dynamics in the symptoms of “Saturation level” and “Cough” as well as the meeting a complex indicator of the therapy effectiveness 2 days earlier than in the control group. The treatment regimen applied also helps to stabilize the level of D-dimer in the blood of the main group patients. Conclusions. The use of two dosage forms of quercetin in addition to the basic therapy accelerates the recovery of patients with coronavirus disease associated pneumonia and can help to prevent the progression of COVID-19 associated coagulopathy.

Background & Aims: Golexanolone is a novel small molecule GABA-A receptor-modulating steroid antagonist under development for the treatment of cognitive and vigilance disorders caused by allosteric over-activation of GABA-A receptors by neurosteroids. It restored spatial learning and motor coordination in animal models of hepatic encephalopathy (HE) and mitigated the effects of intravenous allopregnanolone in healthy adults in a dose-dependent fashion. Herein, we report data on the safety, pharmacokinetics (PK) and efficacy of golexanolone in adult patients with cirrhosis. Methods: Following single/multiple ascending dose studies, adults with Child-Pugh A/B cirrhosis and abnormal continuous reaction time (CRT) on screening were randomized to 3 weeks' dosing with golexanolone (10, 40 or 80 mg BID) or placebo. CRT, psychometric hepatic encephalopathy score (PHES), animal naming test (ANT), Epworth sleepiness scale (ESS) and electroencephalogram (mean dominant frequency [MDF]; delta+theta/alpha+beta ratio [DT/AB]) were obtained at baseline, 10, and 21 days. Results: Golexanolone exhibited satisfactory safety and PK. Baseline characteristics were similar between the 12 and 33 patients randomized to placebo or golexanolone, respectively. By prespecified analyses, golexanolone was associated with directionally favourable changes vs. placebo in ESS (p = 0.047), MDF (p = 0.142) and DT/AB (p = 0.021). All patients also showed directionally favourable changes in CRT, PHES and ANT, but with no statistical difference between golexanolone and placebo. Post hoc analyses taking into account the variability and improvement in CRT, PHES and ANT observed between screening and baseline suggested an efficacy signal by cognitive measures as well. Conclusion: Golexanolone was well tolerated and associated with improvement in cognitive performance. These results implicate GABA-A receptor-modulating neurosteroids in the pathogenesis of HE and support the therapeutic potential of golexanolone. Lay summary: Many patients with cirrhosis experience subtle but disabling cognitive problems, including sleepiness and poor attention span, that impair their ability to be gainfully employed or carry out activities of daily living. This pilot study tested the hypothesis that these problems with cognition, for which there is no approved treatment, might be improved by an experimental drug, golexanolone, designed to normalize the function of receptors which inhibit brain function. The results of this study suggest that golexanolone is well tolerated and may improve cognition, as reflected by measures of sleepiness, attention span and brain wave activity, paving the way for future larger studies of this promising experimental drug. (C) 2021 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.

3 1 Національний фармацевтичний університет, Харків 2 Національний медичний університет імені О.О.Богомольця, Київ 3 ПАТ НВЦ «Борщагівський ХФЗ», Київ Перспективи вивчення застосування препаратів кверцетину в лікуванні COVID-19 У статті наведено етіопатогенетичне обґрунтування щодо доцільності вивчення застосування препаратів кверцетину для профілактики та лікування хворих на COVID-19.На підґрунті даних наукової літератури проведено аналіз особливостей фармакодинаміки кверцетину, які зумовлюють всебічний вплив на перебіг цієї патології, а також супутніх патологічних станів, що виникають внаслідок ускладнень або фармакотерапії загальноприйнятими хіміотерапевтичними та

Вступ. Існують відмінності в підходах до лікування гострого риносинуситу залежно від його провідних клінічних симптомів, зокрема назальної обструкції та лицьового болю. На АТ “Фармак” (Україна) було розроблено новий назальний спрей з водним розчином Енісаміуму Йодиду (ЕнЙ) – оригінальну лікарську форму відомої фармацевтичної речовини. Мета дослідження – визначити ефективність Енісаміуму Йодиду при лікуванні гострого риносинуситу і його переносимість/безпеку. Методи дослідження. Об’єктом дослідження став ЕнЙ (назальний спрей) 10 мг/мл. Як референтний препарат в експериментальній частині роботи було використано BNO-101 під торговою назвою “Sinupret®”. Експериментальний риносинусит відтворено на 24-х кролях (4 дослідні групи по 6 кролів у кожній) у 1-й день дослідження. З 15-ї доби тварини отримували протягом 10-ти діб препарати: 0,9 % фізіологічний розчин (0,1 мл інтраназально) – у групах інтактного контролю та контрольної патології (1-й і 2-й групах відповідно), ЕнЙ (назальний спрей) (0,1 мл інтраназально) – у 3-й групі та BNO-101 (25 мг/мл інтрагастрально) – у 4-й групі. Оцінювали результати лікування на 25-ту добу (лабораторне спостереження, результати аналізу периферичної крові). Клінічну частину роботи проведено у вигляді одноцентрового, рандомізованого, подвійного сліпого, плацебо-контрольованого клінічного дослідження з ескалацією дози – вивчення локальної переносимості та безпеки (I фаза) різних доз нового лікарського препарату ЕнЙ (назального спрею) 10 мг/мл за участю здорових добровольців. Результати й обговорення. На тлі розвитку експериментального риносинуситу за рахунок місцевої дії ЕнЙ (назальний спрей) достовірно позитивно впливав на перебіг патології. Аналіз статистичних даних локальної переносимості свідчить про те, що він не поступався плацебо за показниками “локальна переносимість” та “безпека”, а всі встановлені відмінності були статистично незначущими. Висновки. Отримані результати доклінічного дослідження показали, що, за даними лабораторних спостережень та гематологічних аналізів, Енісаміум Йодид чинить позитивний вплив на перебіг експериментального риносинуситу і при цьому за рівнем активності не поступається препарату порівняння BNO-101. Аналіз статистичних даних клінічного дослідження свідчить про добру переносимість/безпеку використання Енісаміуму Йодиду (назального спрею) 10 мг/мл.

Topicality. Over the past decades, traditional medicines, in particular herbal preparations, have become increasingly widespread worldwide, due to their multivector pharmacodynamics, a high enough level of safety and accessibility to a wide population.Aim. To conduct a preclinical trials to study the analgesic properties of the drug “Arthritan” and phytocomposition based on it.Materials and methods. The study of analgesic properties was carried out under conditions of the development of inflammatory hyperalgesia in 50 rats of both sexes weighing 150-180 g, during which the intensity of the pain reaction was determined according to the Randall-Selitto method. The influence of the studied objects on the course of spontaneous pain response in 40 rats was evaluated in the conditions of acute arthritis in the knee joint.Results and discussion. In the study of analgesic properties in a model of induced pain response in rats with inflammatory hyperalgesia, the combination of “Arthritan”, “Nevrin” and “Nephrolik” showed a high level of analgesic activity, amounted to 30.5 %, significantly exceeded the activity of other drugs. The analgesic activity of the “Arthritan” and “Nevrin” preparations was 20.8 % and 15.9 %, respectively; the “Nephrolik” preparation did not have a significant analgesic effect. Under conditions of the development of a spontaneous pain reaction in rats with acute gonarthritis, the studied phytocomposition showed a high level of analgesic effect with repeated administrations, the activity of which n the 5th day of the experiment was 41.9 %, which significantly exceeds all other means. The preparations “Arthritan” and “Nevrin” showed activity – 19.1 % and 17.9 %, respectively, and the drug “Nephrolic” – 7.8 %, which is an unreliable result. The high level of analgesic activity of the studied phytocomposition is due to the potentiating interaction of its components such as “Arthritan” and “Nevrin”.Conclusions. The results of the studies allow us to recommend further research of the combined preparation containing “Arthritan”, “Nevrin” and “Nephrolik” at a ratio of 1 : 1 : 0.5 as a means of chondroprotective, anti-inflammatory and analgesic action in rheumatological desease profile patients.

Context: Acute kidney injury (AKI) is a common complication of renal pathology and an adverse drug effect. Mortality caused by AKI reaches 80% in some groups of patients. Therefore, the search of the effective agents for AKI treatment is an important task of the pharmaceutical science. Aims: To evaluate the efficacy of various combinations of N-acetylglucosamine (NAG) and quercetin in rats with AKI. Methods: The study was conducted on the model of acute glycerol nephrosis in rats. Combinations of NAG and quercetin in ratios of 1:2, 1:1, 2:1 and 3:1 were studied at a dose of 50 mg/kg with daily intramuscular injection for a week. The efficacy of the combinations was assessed by the indicators of animal survival, excretory renal function, nitrogen metabolism and nephroprotective activity (NA). Results: The combination of NAG and quercetin in the 1:1 ratio was the most effective. There was a significant increase of excretory renal function and normalization of nitrogen metabolism under the influence of this combination. This determined the NA level up to 69.7%, which was the highest value in the presented study. This combination was statistically superior to all others, as well as to quercetin, by the efficacy level. In addition, the combination exceeded the quercetin in NA index by 2.7 times. Conclusions: Thus, the NAG/quercetin combination in 1:1 ratio in injectable dosage form is the most promising for kidney diseases treatment.

The aim. To substantiate the safety using of the new nasal spray with Enisamium Iodide via study results of acute local drug-induced irritant action of the test object single-dose to eyes and nasal cavity mucosa. Material and methods. Enisamium Iodide 10 mg/mL (nasal spray) was the test object. The reference drug was 0.9 % saline. Flemish Giant rabbits were used to induce the experiment (2 groups, 9 rabbits in each group). All study objects were administered in single-dose into the eye conjunctival sacs (0.01 mL) and nasal passages (0.1 mL) by instillation. The eye examination we performed in different time observation point (through 1, 24, 48 and 72 h after drug instillation). Nasal endoscopy was used for control of nasal cavity in all stages of study (15 minutes before, 1-hour and 24 hours after drug instillation) under general anesthesia. The scales of the assessment were used to the result objectivity. Results. The total score was 0 points in all groups at all-time points according to the relevant scale and the scale of the assessment of rabbit nasal cavity mucosa by nasal endoscopy results. This corresponds to the condition of a healthy eye and healthy nasal mucosa. Conclusions. Enisamium Iodide 10 mg/mL (nasal spray) in the single-dose instillation into the rabbit eye conjunctival sacs and rabbit nasal passages did not show local drug-induced irritant action on the eye conjunctiva and nasal cavity mucosa in the experimental animals. Nasal endoscopy could be used as an informative visual method in preclinical studies

In the absence of effective and safety therapy for COVID-19 patients, today the search for new methods of treatment is the most actual topic in medicine and pharmacy. High mortality (7.1 %) due to the development of acute respiratory distress-syndrome, which is caused by cytokine storm, dictate the need to develop a new approaches to the influence on a various pathogenetic links of the disease in the complex therapy of such patients. This review summarizes the data of experimental and clinical studies of the pharmacological properties of quercetin (mechanisms of action, pharmacological effects) and quercetin-containing drugs Quertin and Corvitin (oral and parenteral dosage forms), which are presented on the pharmaceutical market of Ukraine. The results of numerous studies indicate that quercetin has (among others) high anti-inflammatory, antiviral, membrane-stabilizing, immunomodulating and antioxidant effects. The mechanisms for the realization of these pharmacological effects are well studied and make it possible to use quercetin as a pathogenetic therapy (effect on the various pathogenesis links) in patients with coronavirus infection. This dictates the need for the conducting of appropriate clinical trials of these drugs for the prevention and treatment of coronary infection. Clinical trials results may be an innovative strategy in the treatment of COVID-19 patients.

Osteoarthritis (ОА) is a multifactorial disease associated with age, which is characterized by high polymorbidity, level of disability and death. In elderly patients with OA pain therapy especially related to factors such as a significant decrease in physical activity, the presence of comorbid disease (mainly heart disease) and complications caused by irrational drug therapy. Available in an elderly patient OA various somatic diseases and a wide range of treatments used for their medicines suggest the choice of individual treatment strategy that takes into account the ratio of the alleged benefits and possible risks of the purpose of each drug funds in favor of the most safe and effective therapy.

Recently, there has been a trend towards wider use of herbal medicines, which is associated with their pharmacodynamic polytropy, a fairly high level of safety and economic affordability. The aim of the work is the study chondroprotective properties of phytocomposition based on the drug “Artritan” under the conditions of evaluation of the ultrastructure of the cartilage tissue of rats with experimental arthritis. Materials and methods. The study of chondroprotective properties of the investigated phytocomposition based on the drug “Arthritan” was conducted under the conditions of systemic steroid arthritis modeling in rats. Animals received phytocomposition at a conditional therapeutic dose of 0.1 ml/kg. The effectiveness of the phytocomposition was evaluated by the results of the rats' articular cartilage ultrastructure study. Results. The results of the cartilage tissue ultrastructure study in rats with experimental arthritis under the influence of phytocomposition indicate that this drug has a positive effect on the course of systemic steroid arthritis in rats. Moreover, in terms of the degree of influence on the biosynthetic processes in chondrocytes and the structure of the cartilage matrix, it is not inferior to the activity of the reference drug “Arthron Flex”. Phytocomposition causes positive changes, which are manifested by increased biosynthetic processes in the cells. First of all, this is evidenced by the increase in the content of membrane structures in the form of long profiles of granular endoplasmic reticulum and Golgi plate complexes and the disappearance of chondrocytes at different stages of cell death in micropreparations. Conclusions. On the model of systemic steroid arthritis in rats, a positive therapeutic effect of the studied phytocomposition was established along with the well-known chondroprotector “Arthron Flex”, which was confirmed by the improvement of the ultrastructure of the articular tissue.

Acute rhinosinusitis treatment and prevention is connected to the rational choice of drug dosage form, which will provide the therapeutic effect and the safety of a drug substance or a drug substance complex. Nasal spray with Enisamium Iodide can be used to nasal congestion relief in acute rhinosinusitis because the active substance has an anti-exudative action. Nasal endoscopy could be used in experimental rhinology as a method for direct pathology visualization and for evaluation of the effectiveness of test drugs. Aim: To substantiate Enisamium Iodide (nasal spray) 10 mg/mL effectiveness on maxillary sinus ostium via nasal endoscopy in rabbits with experimental rhinosinusitis. Methods: As a test object was used Enisamium Iodide (nasal spray). As a reference drug, we used BNO-101. Experimental rhinosinusitis was induced in the 1st day. On the 1st , 15th and 25th days in all groups (four groups, six rabbits in each group), we used nasal endoscopy and semi-quantitative assessment to the result objectivity. Results: The total score in the intact control group was 0 (0÷0) on the 15th and 25th days (physiological state). The total score in the control pathology group was 2.0 (2.0÷2.0) and 2.0 (1.0÷2.0) (severe rhinosinusitis) respectively. The total score in Enisamium Iodide treated group was 2.0 (1.0÷2.0) (severe rhinosinusitis) and 0.0 (0.0÷1.0) (physiological state). The total score in BNO-101 treated group was 2.0 (1.0÷2.0) (severe rhinosinusitis) and 1.0 (1.0÷1.0) (mild rhinosinusitis). Conclusions: Nasal endoscopy can be used as an informative visual method. Enisamium Iodide (nasal spray) has been shown a positive effect by endoscopic evaluation of maxillary sinus ostium and exceeded activity of the reference drug.

INTRODUCTION:The high world prevalence of rhinosinusitis (RS) initiates the ways of a favorable search for effective and safe medicines for its pathogenetic treatment. The important part of this process is the choice of the most comfortable dosage form, which will enhance therapeutic compliance and ensure the appropriate medicine efficacy and safety. AIM:To substantiate the efficacy of a new nasal spray with anti-inflammatory properties containing Enisamium Iodide (EI) at a concentration of 10 mg/mL by histomorphological study of the nasal cavity and paranasal sinuses mucosal in rabbits with experimental rhinosinusitis (ERS). METHODS:EI (nasal spray) was a test object. Sinupret® was a reference drug. ERS was induced in rabbits on the first day of the study by tamponade of the right half of the nasal cavity under general anesthesia. The study was performed using 24 rabbits (4 groups, 6 rabbits in each group). The histomorphological examination was performed on the 25th day of the study by the standard light microscopy methods. RESULTS:The histomorphological examination of EI 10 mg/mL (nasal spray) impact on RS in rabbits, which administered during 10 days intranasally, revealed the significant therapeutic effect presented by reduced inflammation signs in the epithelium of the nasal cavities and paranasal sinuses mucosal. Besides, the EI impact was not inferior to the reference drug Sinupret® in tablets. The study of the pharmacological properties of the EI (nasal spray) on ERS showed the high rate of onset of EI actions when used intranasally which was superior to the rate of actions of the reference drug Sinupret® (tablets) administered intragastrically. CONCLUSION:The EI (nasal spray) is a promising drug for a pathogenetic therapy of acute RS, which demands further pre-clinical and clinical studies aiming to substantiate its implementation to the clinical practice.